We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry: EMA Should Use Real-World Evidence to Track Drug Safety
Industry: EMA Should Use Real-World Evidence to Track Drug Safety
The European Medicines Agency should focus on real-world evidence and big data to assess the impact of the agency’s pharmacovigilance activities on industry.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor